Huland E, Schwaibold H, Klän R, Huland H
Department of Urology, University of Hamburg-Eppendorf, Germany.
Urology. 1995 Jan;45(1):54-7; discussion 57-8. doi: 10.1016/s0090-4295(95)96582-3.
Quantitative pattern of 486p 3/12 antigenicity in urine cytologies (Quic) of patients with superficial bladder carcinoma during operation and chemoprophylaxis was evaluated to determine the duration of prophylaxis on an individual patient-oriented basis.
Thirty-six patients with superficial bladder carcinoma during chemoprophylaxis (43 [range, 3 to 90] weeks of mitomycin C) have been evaluated monthly for 99 (range, 36 to 141) weeks.
Only 6 of 36 patients (16.7%) had tumor recurrence after mean follow-up of 67.5 weeks. During mitomycin instillations, only 5 patients converted from positive to repeated negative Quic. None of them developed tumor. Thirty-one did not convert and only 6 of them developed recurrent tumor.
Quic seems not to be a reliable marker during mitomycin prophylaxis. After mitomycin prophylaxis, a repeated positive Quic, however, was associated with a high risk of recurrence occurring in 3 of 8 Quic-positive patients. A repeated negative or alternating Quic identified a lower risk group, showing 3 recurrent tumors in 28 patients only. We conclude that Quic cannot be used during, but after, prophylaxis to identify risk patients requiring further treatment. During prophylaxis, its value is limited to a subgroup of patients developing negative Quic, for whom prophylaxis can be stopped individually.
评估浅表性膀胱癌患者在手术及化疗预防期间尿液细胞学检查中486p 3/12抗原性的定量模式（Quic），以确定基于个体患者的预防持续时间。
对36例在化疗预防期间（丝裂霉素C治疗43[范围，3至90]周）的浅表性膀胱癌患者进行了为期99（范围，36至141）周的每月评估。
36例患者中仅6例（16.7%）在平均随访67.5周后出现肿瘤复发。在丝裂霉素灌注期间，仅有5例患者的Quic从阳性转为反复阴性。他们均未发生肿瘤。31例未转变，其中仅6例发生复发性肿瘤。
在丝裂霉素预防期间，Quic似乎不是一个可靠的标志物。然而，在丝裂霉素预防后，Quic反复阳性与8例Quic阳性患者中有3例复发的高风险相关。Quic反复阴性或交替出现则确定了一个低风险组，仅28例患者中有3例出现复发性肿瘤。我们得出结论，Quic不能在预防期间使用，但可在预防后用于识别需要进一步治疗的风险患者。在预防期间，其价值仅限于Quic转为阴性的亚组患者，对于这些患者可单独停止预防。
